Skip to main content

Catalyst Calendar

Tue, Aug 4, 2026

2 updates

9:41 PM

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

gilead.com

4:01 PM

Gilead Sciences Announces Second Quarter 2026 Financial Results

gilead.com

Fri, Jul 24, 2026

1 updates

6:26 AM

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

gilead.com

Tue, Jul 21, 2026

3 updates

4:05 PM

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

gilead.com

10:00 AM

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

gilead.com

10:00 AM

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

gilead.com

Wed, Jun 24, 2026

1 updates

4:29 PM

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

gilead.com

Tue, Jun 23, 2026

1 updates

7:45 AM

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

gilead.com

Mon, Jun 15, 2026

1 updates

4:34 PM

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

gilead.com

Fri, Jun 12, 2026

1 updates

8:30 AM

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

gilead.com

Thu, Jun 11, 2026

1 updates

8:30 AM

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

gilead.com

Mon, Jun 8, 2026

2 updates

4:35 PM

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Trial Results • Phase 3gilead.com

4:30 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

gilead.com

Fri, Jun 5, 2026

1 updates

3:00 AM

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

gilead.com

Thu, Jun 4, 2026

1 updates

4:15 PM

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

gilead.com

Tue, Jun 2, 2026

1 updates

8:30 AM

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Trial Results • Phase 3gilead.com